版本:
中国

BRIEF-Abbvie announces positive phase 2B data on investigational medicine Elagolix

April 7 Abbvie Inc

* Abbvie announces positive phase 2B data demonstrating investigational medicine Elagolix significantly reduced heavy menstrual bleeding in women with uterine fibroids

* Abbvie Inc says phase 3 trials for management of uterine fibroids are ongoing

* Abbvie Inc says study met primary efficacy endpoint

* Abbvie says data demonstrated elagolix, with & without add-back therapy, met primary efficacy endpoint of reduced heavy menstrual bleeding versus placebo Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐